Evidence map›Paper›PMID 33205707›Full record

ArticleVeterinary pathology2021

Temporospatial Development of Neuropathologic Findings in a Canine Model of Mucopolysaccharidosis IIIB.

Tyler A Harm, Shannon J Hostetter, Ariel S Nenninger, Bethann N Valentine, N Matthew Ellinwood, Jodi D Smith

Open access · greenAbstract read
In one paragraph

Article in Veterinary pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tyler A Harm70724Iowa State University, Ames, IA, USA.
Shannon J Hostetter70724Iowa State University, Ames, IA, USA.
Ariel S Nenninger70724Iowa State University, Ames, IA, USA.
Bethann N Valentine70724Iowa State University, Ames, IA, USA.
N Matthew Ellinwood70724Iowa State University, Ames, IA, USA.
Jodi D Smith70724Iowa State University, Ames, IA, USA.ORCID 0000-0001-7952-8024
Iowa State University · USUniversity of Georgia · US

Funding

Phenotypic Effects of Brain-Directed Enzyme Therapy for Sanfilippo B SyndromeR01NS088766 · NINDS · WASHINGTON UNIVERSITY · PI DICKSON, PATRICIA I · 2015 to 2019
$1.7M
Neuroimaging and Neuropathology of Mucopolysaccharidosis IR01NS085381 · NINDS · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI DICKSON, PATRICIA I · 2013 to 2017
$1.6M
NINDS NIH HHS R01 NS085381NINDS NIH HHS R01 NS088766
6 · The paper itself

Abstract

Mucopolysaccharidosis (MPS) IIIB is a neuropathic lysosomal storage disease characterized by the deficient activity of a lysosomal enzyme obligate for the degradation of the glycosaminoglycan (GAG) heparan sulfate (HS). The pathogenesis of neurodegeneration in MPS IIIB is incompletely understood. Large animal models are attractive for pathogenesis and therapeutic studies due to their larger size, outbred genetics, longer lifespan, and naturally occurring MPS IIIB disease. However, the temporospatial development of neuropathologic changes has not been reported for canine MPS IIIB. Here we describe lesions in 8 brain regions, cervical spinal cord, and dorsal root ganglion (DRG) in a canine model of MPS IIIB that includes dogs aged from 2 to 26 months of age. Pathological changes in the brain included early microscopic vacuolation of glial cells initially observed at 2 months, and vacuolation of neurons initially observed at 10 months. Inclusions within affected cells variably stained positively with PAS and LFB stains. Quantitative immunohistochemistry demonstrated increased glial expression of GFAP and Iba1 in dogs with MPS IIIB compared to age-matched controls at all time points, suggesting neuroinflammation occurs early in disease. Loss of Purkinje cells was initially observed at 10 months and was pronounced in 18- and 26-month-old dogs with MPS IIIB. Our results support the dog as a replicative model of MPS IIIB neurologic lesions and detail the pathologic and neuroinflammatory changes in the spinal cord and DRG of MPS IIIB-affected dogs.

Indexed as

Dog DiseasesMucopolysaccharidosesMucopolysaccharidosis IIIAnimalsBrainDisease Models, AnimalDogsHeparan SulfateHeparan Sulfateanimal models of human diseasecerebrospinal fluiddogsgliosishistologylysosomal storage diseasemucopolysaccharidosis IIIBneuroinflammationphysiopathologySanfilippo syndrome

Identifiers

PMID33205707
PMCPMC8369529
OpenAlexW3102104545

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.